1. Home
  2. ELBM vs CRDL Comparison

ELBM vs CRDL Comparison

Compare ELBM & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electra Battery Materials Corporation

ELBM

Electra Battery Materials Corporation

HOLD

Current Price

$1.18

Market Cap

87.9M

Sector

Miscellaneous

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELBM
CRDL
Founded
2011
2017
Country
Canada
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.9M
97.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ELBM
CRDL
Price
$1.18
$1.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$2.15
$9.00
AVG Volume (30 Days)
978.5K
333.1K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$0.77
52 Week High
$8.70
$1.59

Technical Indicators

Market Signals
Indicator
ELBM
CRDL
Relative Strength Index (RSI) 68.72 52.69
Support Level $0.88 $0.94
Resistance Level $0.97 $1.08
Average True Range (ATR) 0.07 0.05
MACD 0.03 0.01
Stochastic Oscillator 94.74 55.88

Price Performance

Historical Comparison
ELBM
CRDL

About ELBM Electra Battery Materials Corporation

Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: